Mitochondrial damage by antiretrovirals: Diagnosis and monitoring;Toxicidad mitocondrial de los antirretrovirales: Diagnóstico y monitorizacíon

Medicina Clinica

Volumn 121, Issue 8, 2003, Pages 310-315

  de Mendoza, Carmen ^a   Blanco, Francisco ^a   Soriano, Vicente ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

HAART; Lactic acidosis; Mitochondria; mtDNA

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; FATTY ACID; HYDROXYL GROUP; LACTIC ACID; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; PYRUVIC ACID; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

AEROBIC METABOLISM; CARBOHYDRATE METABOLISM; CYTOTOXICITY; DIAGNOSTIC PROCEDURE; DNA CONFORMATION; DRUG MONITORING; DYSLIPIDEMIA; EXPERIMENTAL DESIGN; FATTY LIVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPID METABOLISM; LIPODYSTROPHY; MITOCHONDRION; MYOCARDIAL DISEASE; MYOPATHY; NEUROLOGIC DISEASE; NONHUMAN; PANCREATITIS; PANCYTOPENIA; PROGNOSIS; REVIEW; VIRUS PATHOGENESIS;

EID: 0141839671     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050704     Document Type: Review

References (35)

1. Dalakas M, Illa I, Pezeshkpour G, Laukaitis J, Cohen B, Griffin J, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1089-105.
2. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-22.
3. Medina D, Tsai C, Hsiung G, Cheng Y. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three HIV dideoxynucleosides. Antimicrob Agents Chemother 1994;38:1824-8.
4. Benbrik E, Chariot P, Bonavaud S, Ammi-Said M, Frisdal F, Rey C, et al. Cellular and mitochondrial toxicity of AZT, ddI, and ddC on cultured human muscle cells. J Neurol Sci 1997;149:19-25.
5. Brinkman K, Ter Hofstede H, Burger D, Smeitink J, Koopmans P. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
6. Vittecoq D, Jardel C, Barthélémy C, Escaut L, Cheminot N, Chapin S, et al. Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or casual disorder? J Acquir Immune Def Syndr 2002;31:299-308.
7. Jenuth J, Peterson A, Fu K. Radom genetic drift in the female germline explains the rapid segregation of mammalian mitochondrial respiratory control: A correlated clinical, biochemical, and morphological study. J Clin Invest 1962;41:1776-804.
8. Horn T. Mitochondrial toxicity in HAART. PRN Notebook 2002;7:15-20.
9. Chinnery P, Howell N, Andrews R, Turnbull D. Clinical mitochondrial genetics. J Med Genet 1999;36:425-39.
10. Munnich A, Rustin P, Roting A, Chretien D, Bonnefont J, Nuttin C, et al. Clinical aspects of mitochondrial disorders. J Inherit Metab Dis 1992;15: 448-55.
11. Johns D. Mitochondrial DNA and disease. N Engl J Med 1995;333:44-63.
12. Johns D. The other human genome: mitochondrial DNA and disease. Nat Med 1996; 10: 1065-8.
13. Wallace D. Mitochondrial genetics: a paradigm for aging and degenerative disease? Science 1992;5057:628-32.
14. Yeni P, Hammer S, Carpenter C, Cooper D, Fischl M, Gatell J, et al. Antiretroviral treatment for adults with HIV infection in 2002. JAMA 2002; 288:222-35.
15. Birkus G, Hitchcock M, Cihlo T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46: 716-23
16. Chariot P, Gherardi R. Myopathy and HIV infection. Curr Opin Rheumatol 1995;7:497-502.
17. Casademont J, Barrientos A, Grau J, Pedrol E, Estivill X, Urbano-Márquez A, et al. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain 1996;119: 1357-64.
18. Chariot P, Drogou I, De Lacroix-Szmania I, Elizer-Vanerot M, Chazand B, Lombes A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999;30:156-60.
19. Harris M, Chan K, Tesiorowski A, Hogg R, Rosenberg F, Yan C, et al. Random venous lactate levels among HIV-positive patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31:448-50.
20. Ct̂oé H, Brumme Z, Craib K, Math M, Alexander C, Wynhoven B, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20.
21. Blanco F, García-Benayas T, De la Cruz J, Gonzélez-Lahoz J, Soriano V. First-line therapy and mitochondrial damage: different nucleosides, different findings [in press]. HIV Clin Trial 2003.
22. Lonergan J, Havlir D, Barber E, Mathews W. Incidence of symptomatic hyperlactatemia in HIV-infected adults on NRTIs [abstract 35]. Proceedings of 9th Conference on Retrovirus and Oportunistic Infections, Seattle 2002.
23. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13: 1659-7.
24. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-F32.
25. Brinkman K, Smeitink J, Romijn J, Reiss P. Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy related lipodystrophy. Lancet 1999;354:1112-5.
26. Urso R, Gentile M. Are «buffalo hump» syndrome, Madelung's disease and multiple symmetrical lipomatosis variants of the same dysmetabolism? AIDS 2001;15:290.
27. Mallal S, John M, Moore C, James I, McKinnon E. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
28. Moyle G, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard B. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and posible risk factors. AIDS 2002;16:1341-9.
29. Lonergan T, McComsey G, Hessenthaler S. Lack of recurrence of symptomatic and asymptomatic hyperlactatemia when stavudine is replaced by either abacavir or zidovudine: 48 weeks data. Antiviral Ther 2002;7: L13.
30. Mallal S, Nolan D. Light and electron microcoscopy findings in subcutaneous fat in antiretroviral treated and naive HIV-infected patients [abstract Lb-PeB7054]. 13th International AIDS Conference. Durban, South Africa, 2000.
31. Miller K, Cameron M, Wood L, Dalakas M, Kavacs J. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000;133:192-6.
32. Walker U, Bickel M, Lütke Volksbeck S, Ketelsen U, Schöfer H, Setzer B, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immun Def Syndr 2002;29:117-21.
33. Casula M, De Baar M, Van Gemen B, De Ronde A, Timmermans E, Dobbelaer-Bosboom, et al. Therapy with efavirenz + ritonavir-boosted indinavir, with or without stavudine after 24 weeks does not decrease mtDNA and mtRNA content of PBMC assessed by single tube duplex real-time NASBA. Antiviral Therapy 2002;7:L16.
34. McComsey G. Updated on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy. AIDS Reviews 2002;4:140-7.
35. De Ronde A, Van Gemen B, Casula M, Timmermans E, Van Dooren M, Westrop M, et al. Decline of mitochondrial DNA during therapy with nucleoside analogue reverse transcriptase inhibitors assessed by a single-tube NASBA simultaneously assaying both mitochondrial and nuclear DNA. Proceedings of [abstract WeOrB1305]. 14th International AIDS Conference, Barcelona, 2002.